Stem Cell Therapy advancements, page-476

Oh what might have been (and still an outside chance):

https://www.fiercepharma.com/pharma/jjs-car-t-partner-legend-biotech-reportedly-receives-buyout-offer

(J&J partnered with Legend in its genetically modified autologous T cell immunotherapy treatment for myeloma patients - with obvious reference to the research collaboration in ATI with J&J, which we understand is being shopped around in the US at last disclosure)

I missed a report on autologous MSC stem cells in the treatment of Achilles tendinopathy:

https://www.nature.com/articles/s41598-024-61399-3

I won't patronise OCC investors as to why tenocytes are so more obviously the more efficacious choice in tendinopathies - its well covered above for those who don't know. Oh ATI, wherefore art thou at? Lets hope we get a little more clear clarification of it and all business developments and strategies in the forthcoming annual results, rather than a casual vague chat with Alan Kohl, that the vast majority of investors could have so easily missed - including me.